Introduction
Boron neutron capture therapy (BNCT) is a type of radiotherapy with the aim of selectively killing cancer cells while reducing the side effects of conventional radiotherapy methods. The procedure of BNCT involves targeting of 10 B (15-30 ppm) to tumor tissue, irradiation of 10 B with thermal or epithermal neutrons (≤10 KeV; ≈10 9 n 0 sec/cm 2 ) followed by the release of 4 He and 7 Li ions in the tumor tissue (see reactions below) [1] . 4 He and 7 Li are characterized by short ranges in tissue, due to their high linear energy transfer (LET) values. For this reason, tumor tissue may be selectively destroyed by the application of BNCT [2, 3] .
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97 exposing healthy tissue adjacent to a tumor site is unavoidable. It is known that X-or Gammaradiations are absorbed also by healthy tissue and not just tumor tissue during radiotherapy. This unwanted exposure during conventional radiotherapy has side effects on the patients.
In particular, for example the neuroendocrine and cardiovascular systems are susceptible to irreversible damage [5] . Although some precautions, such as the collimation of X and gamma radiation and limited dose calculations, are taken, there is no way to fully protect patients from unwanted exposures. In addition, the energy transfer properties of different radiations are also important. Whereas X-and gamma energies are absorbed by the encountered tissue exponentially with depth, the energy absorption curve of neutron and proton is quite different from that of X and gamma radiation [6] . If all side effects of X and gamma rays and all of the beneficial uses of neutrons are considered, BNCT is hypothesised to be an alternative radiotherapy method particularly for the treatment of head and neck cancers [6] . The most important challenge associated with BNCT is the targeting of 10 B to the tumor tissue. At present, different strategies and carriers are being used for carrying 10 B to tumor tissue [7, 8, 9] . The glucose analogue 2-deoxy-D-glucose (2-DG) is an inhibitor of glucose transport and glycolytic ATP production. In addition to depleting energy in cells, 2-DG has also been found to alter N-linked glycosylation, which results in unfolded protein responses and the induction of changes in the gene expression and phosphorylation status of proteins involved in signalling, cell cycle control, DNA repair, calcium influx, and apoptosis [10] . It is well known that the glucose metabolism in tumor tissue increases due to, for example, the lack of oxygen, a decreased oxidative phosphorylation, the activation of anaerobic respiration pathway by tumorogenic cells for ATP synthesis, and finally the requirement of excess glucose consumption [11] . Due to the affinity of glucose to tumor tissue, 18 F conjugated glucose ( 18 F-Deoxy-D-glucose) is routinely used for the detection and staging of tumors with positron emission tomography (PET). In this technique, 18 F-DG releases positrons in the tumor tissue and detectors detect the gamma radiation from electron-positron annihilations [7] Boric Acid and Deoxy-D-Glucose has been complexed and 10 BDG [((2R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid] synthesized via pH reaction, complexation yield was found about 80% in our previous studies [12] . As extended research, the antineoplastic properties of 10 BDG were examined in the present study because it is considered as an alternative 10 B carrier for BNCT.
Materials and Methods

Complexation reaction of B(OH) 3 and 2-DG
The complexation reaction of boric acid with polyhydroxyl compounds, such as tiron, has been described in previous studies [13] . First, 0.1 M boric acid (B(OH) 3 ; Sigma-Aldrich, B6768) and 0.5 M deoxy-D-glucose (DG: Sigma-Aldrich, D8375) solutions were prepared with the same volumes of deionised water and incubated for one hour at pH 3 and 50°C.
B(OH) 3 Both solutions were then mixed in the same tube and incubated for one hour at pH 3. The pH was gradually increased from pH 3 to pH 7 and stabilised at a physiologic value of pH 7.4. The ]
10 BDG complexation reaction was tested using a Fourier Transform Infrared Attentuated Total Reflectance spectroscopy (FT-IR/ATR), as previously described (Figs. 1a, 1b , and 1c) [13] . The Accelrys Discovery Studio Visualiser software (version 3.5) was used for the molecular simulations. The synthesized molecule was named according to the International Union of Pure and Applied Chemistry (IUPAC) rules for naming [14, 15] . Name: BDG; 10 BDG ( Figure 1a ); IUPAC Name: ((2R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)boronic acid BDG molecular weight: 193.953; exact BDG molecular weight: 194.06; molecular formula: C 6 H 11 BO 7 [15] . [17] .
Evaluation of apoptotic pathway triggered by 10 
BDG for the NCI-H209 cell line
Due to its high metastatic characteristics and its insensitivity to chemotherapy, the NCI-H209 small-cell lung cancer cell line was chosen to triggered pathway analysis by the 10 BDG. To examine the cytotoxic pathways induced by 10 A total of 10 6 NCI-H209 cells were seeded in a 6-well plate and incubated for 24 hours. After the medium was changed, defined concentrations of 10 BDG were added in fresh growth medium [RPMI 1640, Hyclone RPMI 1640 with HEPES/L-GLU SH30255 and 1% Pen/Strep solution (Biological Industries, 10,000 U/mL Pen, 10 mg/mL Strep, Kibbutz Beit HaEmek, Israel 25115)]. After threehour incubation with 10 BDG, 10 6 H209 cells were collected and washed with phosphate buffered saline (PBS). The solution of the caspase assay kit was then added to the suspended cells, and the samples were incubated for 30 minutes in a CO 2 incubator at 37°C. The cells were collected and washed three times with 1X apoptosis wash buffer according to the protocol recommended by the kit's manufacturer, and analyzed using a fluorescence plate reader (Perkin Elmer, EnSpire Multimode Plate Reader Label-free System).
PARP cleavage examination of the NCI-H209 cell line
The PARP cleavage was tested with a western blot analysis. First, 10 6 NCI-H209 small cell lung cancer cells (ATCC® HTB-172™) were incubated with 10 BDG solution in growth medium (RPMI 1640 R8758-Sigma, 10% FCS, 0.5% Pen/Strep, Sigma-Aldrich). The cells were collected after three hours and washed with PBS. The cells were then lysed with 100 µl of lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, and 5% glycerol). Then, 100 µg of the total protein lysates were loaded onto a mini SDS-PAGE gel (4% stacking gel and 10% separating gel). The proteins were blotted onto nitrocellulose membrane using a semidry transfer system. The membrane was incubated with blocking solution for 30 minutes. The membrane was then incubated overnight with the primary antihuman PARP antibody and the β-actin antibody. The membrane was then incubated for three hours with the alkaline phosphate-conjugated secondary antibody, and the BCIP/NBT solution was used for the detection of the PARP and β-actin bands. The ImageJ software (1.44p National Institute of Health, USA) was used for the analysis of the intensities of the PARP protein band.
Examination of apoptotic DNA damage of the NCI-H209 cell line
The DNA damage was tested using the TUNEL assay (Invitrogen, mp2310, APO-BrdU™ TUNEL Assay Kit). First, 10 6 NCI-H209 small cell lung cancer cells (ATCC® HTB-172™) were incubated with 10 BDG in the growth medium (RPMI 1640 R8758-Sigma, 10% FCS, 0.5% Pen/Strep, Sigma-Aldrich). After three hours, the cells were collected and washed with PBS. The experimental procedure followed to detect DNA damage was the protocol recommended by the manual for the TUNEL assay kit.
First, 25 x 10 4 cells were seeded in 6-well plates and treated with 10 BDG for three days. The conditioned media and trypsinized cells were placed in a 15-ml falcon tube and centrifuged at 1000 x g and RT for five minutes. The pellet was washed with cold PBS and centrifuged again at 1000 x g and RT for five minutes. The pellet was dissolved in 120 µl of lysis buffer (10 mM Tris pH 7.4, 100 mM NaCl, 25 mM EDTA, and 1% Nlauryl sarcosine) by gentle-vortexing and 4 µl of proteinase K (10 µg/µL) was then added. After the sample was incubated at 45°C for 2 h, 2 µl of RNAse (10 µg/ml) was added, and the cell lysates were incubated for one hour at room temperature. The lysate was run on a 2% agarose gel with N', 
Proliferation assay of the NCI-H209 cell line
To examine the antiproliferative properties of 10 BDG and its additive effect with antineoplastic drugs (AMD), the MTT proliferation assay was applied. Cells of the NCI-H209 small lung cancer cell line were incubated with/without 20 mM 10 BDG and 2.5 mM AMD for 72 hours. At the end of the 10 BDG incubation (at the indicated times), 1/10 MTT solution was added to the cells, and the cells were incubated for one hour in a CO 2 incubator. The RPMI medium was removed with a centrifuge, and the purple MTT-formazan crystals were dissolved through the addition of 100 μl of DMSO. The purple colour was read at 570 nm using a microplate reader (Thermo Multiskan EX, Shanghai-China).
Examination of genotoxicity with plasmid DNA damage assay 250 ng of plasmid DNA (''8454 pCMV-VSV-G'') and 10 BDG (0, 20, 40, 80, and 160 µM ) were added to a tube containing 2 µl of resuspended DNAse inactivation reagent (Ambion, AM1906). The mixtures were adjusted with double distilled H 2 O to obtain a final concentration of 20 µl. Those mixtures were mixed well and centrifuged at an acceleration of 11,000 g, incubated at room temperature for 1.5 minutes and the contents were then transferred to another tubes and incubated for 24 hours and one week at 37°C. The reaction mixtures were loaded into a 1% agarose gel containing 0.5 µg/ml of ethidium bromide (Et-Br). 20 cm long gels were run at 6 V/cm for two hours.
Bearing tumor tissue in Copenhagen Rats (MAT-LyLu cell line)
Copenhagen Rat tumor model with MATLyLu cell line implantation is very useful for biodistribution and drug target studies [18] . Cancer tissue formation was induced by injection of 1x10 6 MAT-LyLu cells into the left peritoneum of Copenhagen Rats, to examine whether 2-DG has carrier properties for 10 B to cancer tissue (MATLyLu: Rat prostate Adenocarcinoma cell line was a kind gift from Prof. Dr. Seyhan Altun, İstanbul University: ATCC JHU-92). Copenhagen Rats were anesthetized by the ketamine injection (100 mg/kg) previous to the cell injection. An average tumor size of 1 cm was achieved in seven days.
Biodistribution of
B in the tumor tissue
At the seventh day, tumor induced rats were subjected to diet for four hours and anesthetized by using ketamine (200 mg/kg) previous 10 BDG injection. Boric Acid (B(OH) 3 ) and/or 10 BDG solution were administrated to the rats having a body mass of 150 g via tail vein ( 10 B 30 mg/kg). Indicated tissues (Brain, Lung, Liver, Blood, Colon) including tumor tissue were taken after 40 minutes from 10 BDG injection under anesthesia. The tissues were homogenized by mechanical and ultrasonic homogenization. Samples were assayed by inductively coupled plasma atomic emission spectroscopy (ICP-AES, OPTIMA 2000 DV, Perkin Elmer Instruments).
10 B analysis was carried out by the wavelength at 249.772 nm and 7Li analysis was also performed at 670.784 nm [19] .
Statistical analysis
Each experiment was repeated at least four times, and the results of a representative experiment are shown. The T test was applied to the variables, and each result is reported as the mean ± Standard Error of Mean (S.E.M). Statistical significance was accepted at P values of less than 0.05. Permission for the experimental animal study was obtained from the Yüzüncü Yıl University Experimental Animal Research Committee.
Results
Successful complexation reaction of boric acid and deoxy-D-glucose via a low-high pH reaction
In a previous complexation study, the polyhydroxyl compound Tiron (4,5-dihydroxy-1,3-benzenedisulfonic acid disodium salt) and boric acid were complexed using the low-high pH reaction described by Chaoying and coworkers, which was designed for the complexation of boric acid with deoxy-D-glucose ( 10 BDG). To demonstrate the complexation, FT-IR/ATR analyses were used to analyze the 10 B(OH) 3 -DG and 10 B(OH) 3 -Tiron reactions, and the success of the complexations was proven (Figure 1a, 1b, 1c ) [13] .
Cytotoxicity of 10 BDG
The cytotoxic levels of synthesized 10 BDG were tested on different cancer cell lines (HT29, MCF-7, Raji and H209) using the MTT assay (Fig.  2) , the absorbance at 570nm was determined by spectrotometry. The growth inhibition rate was calculated as follows: Growth inhibition rate (％) = (1-OD570 experiment/D570 control) ×100％.
The cytotoxicity values of 10 BDG after three and 24 hours were found to be very close to those reported in the literature for the cytotoxicity of 10 B(OH) 3 (Table 1 
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The main two caspase streams (caspase-8 and caspase-9) were studied on NCI-H209 cell line. It is known that caspase-3 may be activated by both caspase-9 and caspase-8. In the present study, 10 BDG-induced caspase-9-dependent caspase-3 activation was observed (Figs. 3 and 4) . These findings suggest that 10 BDG can trigger the mitochondrial apoptotic pathway and that the targeted cells can be destroyed through the apoptotic mechanism.
PARP cleavage determination
Poly ADP ribose polymerase (PARP) is an enzyme between the caspase stream and DNA ligases which cleavage of PARP results in DNA fragmentation. Also, PARP cleavage indicates the activation of the apoptosis mechanism, and western blot analyses revealed that 10 BDG induced PARP cleavages in H209 small cell lung cancer cells (ATCC® HTB-172™; Figs. 5 and 6) in a dosedependent manner.
Examination of apoptotic DNA damage through flow cytometer
The activation of the caspase stream and PARP should result in DNA fragmentation. To examine the DNA fragmentation, the TUNEL assay and the DNA fragmentation agarose gel assay were used. These assays revealed that 10 BDG-induced DNA fragmentation was present in NCI-H209 small lung cell carcinoma cells in a dose-dependent manner (Figs. 7 and 8 ).
Proliferation assay
The inhibition of proliferation is the main target of antineoplastic drugs [20] (Shapiro et al., 1999) . To analyze the effects of 10 BDG on proliferation, NCI-H209 small lung carcinoma cells were used. Actinomycin D (ActD) inhibits DNAdependent RNA polymerases, may also induce apoptosis at high concentrations [21] (Fraschini et al., 2005) , and inhibits proliferation [22] (Xu and Krystal, 2010) . Even it does not seem to be statistically significant, the simultaneous exposure of H209 cells to 10 BDG and ActD demonstrates that 10 BDG may act synergistically with chemotherapeutics such as ActD and more effective results may be obtained with low dose chemotherapeutics (Fig. 9) .
Examination of genotoxicity with plasmid DNA damage assay
Genotoxins/Carcinogens are a broader category of substances that induce DNA damage and changes to the structure or number of genes via chemical interaction with DNA. It is obvious that any synthesized molecules with therapeutic aims should not be genotoxic. To define the genotoxic/carcinogenic properties of 10 BDG, the plasmid DNA fragmentation assay was used. The results revealed that 10 BDG did not induce any plasmid DNA fragmentation, as determined through agarose gel affinity chromatography (Fig. 8) . In contrast, the previous analyses had revealed that 10 BDG induced DNA fragmentation in NCI-H209 cells. Based on these two results (Figs. 8, 10 ), 10 BDG does not have genotoxicity but does exhibit apoptotic properties. Thus, 10 BDG looks appropriate for in vivo BNCT applications (Fig.  10) . Tumor selective cytotoxic biological compounds may be a useful approach to avoid cumulative side effects of concomitant use of chemotherapeutics.
Build-up Tumor Tissue in Copenhagen Rats
To examine whether 2-DG has carrier properties for 10 B to cancer tissue, cancer tissue formation was induced with injections of MATLyLu cells to the left peritoneal of Copenhagen Rats. Copenhagen Rats were anesthetized by ketamine (100 mg/kg) before cell injection. It was observed that the induced tumors were about 1 cm in diameter after seven days.
Biodistribution of 10 B
The ICP-OES results demonstrate that the boron content of different tissues and blood was about 5 ppm in the all tissues and in the tumor of the control group (Fig. 11) 10 BDG injection (Fig. 11) .
Discussion
Since the 1960s, researchers have exhibited a growing interest in BNCT due to the increase of cancer incidence worldwide. The success of BNCT depends on two factors [23] : (1) neutron production at an appropriate dose and energy and (2) delivery of sufficient amounts of 10 B specifically to the tumor tissue [24] . So far, a wide variety of boron delivery agents have been synthesized [25] and tested, but only two drugs (BSH and BPA) have been used in clinical trials: Since 1968, a polyhedral borane anion, which is known as sodium borocaptate or BSH (Na 2 B 12 H 11 SH), has been used in Japan [26] . To plan an improved radiation therapy, boron phenylalanine (BPA), which is a dihydroxyboryl derivative of phenylalanine, with or without mannitol was used for the treatment of patients with glioblastoma [27] .
The use of boric acid supplements is another approach to preparation of the patients for BNCT. In vivo epidemiologic studies have shown that boron and boric acid affect human health. As defined previously, 98.4% of the boron in the blood is found in the form of boric acid [28] . According to several studies, the supplementation of food with boron reduces the risk of some cancers [29, 30] . Moreover, Gallardo-Williams et al. showed that additional boron taken with food reduces the size of tumors and the level of IGF-I in rats [31] . Acerbo and Miller reported that boron prevents the proliferation of cancer cells in melanoma [32] . Henderson and co-workers confirmed that a high level of boric acid in the blood reduces the risk of prostate cancer by reducing the level of Ca ++ in cells and signal transmission [33] . Scorei and co-workers demonstrated the antiproliferative effects of boric acid and calcium fructoborate (the form of boron in food) in breast cancer cells and also showed that calcium fructoborate induces apoptosis [34] . Hsu and co-workers showed that boric acid may be helpful for the treatment of bone cancers because it has cytotoxic effects and it accumulates in bones [19] .
An increasing number of successful results have been found for boric acid and BNCT in clinical trials. For instance, Wang et al. showed that BNCT treatment has positive effects on head and neck cancers and that the lifespan of a patient may be extended with BNCT [35] . In phase I and phase II studies, a significant reduction in the size of the tumor was confirmed in all patients, and the side effects were evaluated as tolerable. In addition to BNCT alone, the synergistic effects of BNCT with classic radiation treatment in glioblastoma are being studied in phase II studies. [36, 37] .
Boron targeting to tumor tissue is an important problem and likely the most important challenge associated with BNCT. To solve this problem, different carrier molecules have been used to increase the rate of boric acid passing into cancer cells and to minimize the damage to normal cells. Porphyrin [38] , polyamines based on polylysine [39] , and fructose [40] are some of molecules that increase the selectivity and anticarcinogenic effects of boron.
Although boron has some effects on tumorigenic tissues and cells, it has no tumorselective properties and is thus not convenient for BNCT applications. Thus, the research priority for BNCT is to synthesize tumor-selective boron. Large-scale boron carriers, such as carboranecontaining porphyrins and cholesterolmetallacarboranes bearing cobalt, iron, and chromium, were designed and tested in previous studies [41, 42] .
The main two challenges associated with the identification of appropriate carriers are the toxicity of the newly synthesized molecules and the carrier properties of boron to tumor tissue. The evaluation of the accumulation of boron in different tissues demonstrates that liver toxicity is the problem that is most encountered by the tested carriers [41, 42] .
2-Deoxy-d-glucose contains poly-hydroxyl compounds, and its complexation with boric acid ( 10 BDG) was achieved in the present study through a pH reaction, as previously described for boric acid complexation with poly-hydroxyl compounds [13] .
In the present study, cytotoxic levels of 10 BDG were evaluated on different cancer cell lines, and it was found that 10 BDG triggered the activation of the apoptotic pathway that involves caspase 9 and caspase 3. Western blot analysis revealed PARP cleavage, and the TUNEL assay and flow cytometer were used to demonstrate the existence of protolytic DNA damage caused by PARP-induced DNA ligase.
It is known that the most significant feature of tumor tissue is uncontrolled excessive mitosis and ATP requirements. An increase in the tumor tissue biomass also increases the energy needs and decreases the oxygen supplies. Consequently, the required ATP is produced through anaerobic pathways [11] . The yield of the anaerobic synthesis of ATP is very low and leads to an increased glucose consumption rate [43] .
Due to the affinity of glucose to tumor tissue, glucose-complexed drugs are currently an intensive interest area for antineoplastic drug studies. In the present study, a type of glucose derivative (2-DG) was used as boron carrier to selectively target tumor tissue.
For biodistrubition studies in the experimental animal model, boron dose application varies between 25-50 mg 10 B/kg in different studies [19] . IC 50 , IC 1 and calculated LD 50 , LD 1 values may be useful to calculate optimum non-toxic application dose for biodistribution studies on rats; however, further in vivo investigations are needed to define maximum applicable doses before proceeding to clinical applications.
Hsu and co-workers recommend use of boric acid for osteosarcoma tumors. However, in the present study, tumor selectivity of boric acid was not observed for both soft tissues and adenocarcinoma metastatic prostate tumor tissue. The results obtained in the present study on the control group support the findings of Hsu and coworkers [19] . Beside biodistribution time-lapse analysis, a synergistic use of different boron carriers such as the simultaneous use of glucose derivative and essential amino acid carriers to achieve the required boron concentration in the tumor tissue could be another strategy to avoid the toxic effect of boron carriers.
Moreover cytotoxicity, genotoxicity and apoptotic pathway studies were performed. No genotoxicity was observed and the cytotoxic mechanism was the caspase-dependent apoptotic pathway. While anti-proliferative properties, induction of apoptosis, etc. would be beneficial, cytotoxicity over the normal tissue is restricting use of new synthesized 10 B carriers. According to the present results, 10 BDG has relatively low cytotoxic values (i.e., the LD50 value is on average 537.50 µM) if compared with chemotherapeutics such as AMD; therefore it seems worth to continue to work on this.
Considering the apoptotic and antiproliferative properties of 10 BDG and the carrier properties of DG, 10 BDG and 10 B 18 FDG, these complexes can be an alternative boron carrier in lieu of boronophenylalanine (BPA) and BSH for BNCT. Consequently, BNCT studies with 10 BDG are currently being performed at the TRIGA MARKII Nuclear Reactor of the Energy Institute at Istanbul Technical University.
